O-GlcNAcylation in Immunity and Inflammation: An Intricate System (Review)

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2019 Jun 15

PMID 31198979

Citations 37

Authors

Yu Li

MingZheng Xie

Lili Men

Jianling Du

Affiliations

Soon will be listed here.

Abstract

Chronic, low‑grade inflammation associated with obesity and diabetes result from the infiltration of adipose and vascular tissue by immune cells and contributes to cardiovascular complications. Despite an incomplete understanding of the mechanistic underpinnings of immune cell differentiation and inflammation, O‑GlcNAcylation, the addition of O‑linked N‑acetylglucosamine (O‑GlcNAc) to cytoplasmic, nuclear and mitochondrial proteins by the two cycling enzymes, the O‑linked N‑acetylglucosamine transferase (OGT) and the O‑GlcNAcase (OGA), may contribute to fine‑tune immunity and inflammation in both physiological and pathological conditions. Early studies have indicated that O‑GlcNAcylation of proteins play a pro‑inflammatory role in diabetes and insulin resistance, whereas subsequent studies have demonstrated that this post‑translational modification could also be protective against acute injuries. These studies suggest that diverse types of insults result in dynamic changes to O‑GlcNAcylation patterns, which fluctuate with cellular metabolism to promote or inhibit inflammation. In this review, the current understanding of O‑GlcNAcylation and its adaptive modulation in immune and inflammatory responses is summarized.

Citing Articles

A pan-cancer analysis of MARCH8: molecular characteristics, clinical relevance, and immuno-oncology features.

Quan Z, Fan S, Zheng H, Ning Y, Yang Y Cancer Biol Ther. 2025; 26(1):2458773.

PMID: 39881438 PMC: 11784653. DOI: 10.1080/15384047.2025.2458773.

O-GlcNAcylation dictates pyroptosis.

Lang Y, Li J, Zhang L Front Immunol. 2025; 15:1513542.

PMID: 39742284 PMC: 11685218. DOI: 10.3389/fimmu.2024.1513542.

O-GlcNAcylation: Crosstalk between Hemostasis, Inflammation, and Cancer.

Vasquez Martinez I, Perez-Campos E, Perez-Campos Mayoral L, Cruz Luis H, Pina Canseco M, Zenteno E Int J Mol Sci. 2024; 25(18).

PMID: 39337387 PMC: 11432004. DOI: 10.3390/ijms25189896.

The circZEB1/miR-337-3p/ axis mediates angiogenesis and metastasis via O-GlcNAcylation and up-regulating in breast cancer.

Wang D, Chen D, Liang L, Hu J Heliyon. 2024; 10(14):e34079.

PMID: 39114035 PMC: 11305230. DOI: 10.1016/j.heliyon.2024.e34079.

The role of O-GlcNAcylation in bone metabolic diseases.

Yang Y, Zhou X, Deng H, Chen L, Zhang X, Wu S Front Physiol. 2024; 15:1416967.

PMID: 38915778 PMC: 11194333. DOI: 10.3389/fphys.2024.1416967.

References

Karin M, Ben-Neriah Y . Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-63. DOI: 10.1146/annurev.immunol.18.1.621. View

James L, Tang D, Ingram A, Ly H, Thai K, Cai L . Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes. 2002; 51(4):1146-56. DOI: 10.2337/diabetes.51.4.1146. View

Yamamoto Y, Gaynor R . IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci. 2004; 29(2):72-9. DOI: 10.1016/j.tibs.2003.12.003. View

Kneass Z, Marchase R . Neutrophils exhibit rapid agonist-induced increases in protein-associated O-GlcNAc. J Biol Chem. 2004; 279(44):45759-65. DOI: 10.1074/jbc.M407911200. View

Kneass Z, Marchase R . Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils. J Biol Chem. 2005; 280(15):14579-85. DOI: 10.1074/jbc.M414066200. View

Gross B, Kraybill B, Walker S . Discovery of O-GlcNAc transferase inhibitors. J Am Chem Soc. 2005; 127(42):14588-9. DOI: 10.1021/ja0555217. View

Pietropaolo M, Barinas-Mitchell E, Kuller L . The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity?. Diabetes. 2007; 56(5):1189-97. DOI: 10.2337/db06-0880. View

Zou L, Yang S, Hu S, Chaudry I, Marchase R, Chatham J . The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels. Shock. 2007; 27(4):402-8. DOI: 10.1097/01.shk.0000245031.31859.29. View

Khidekel N, Ficarro S, Clark P, Bryan M, Swaney D, Rexach J . Probing the dynamics of O-GlcNAc glycosylation in the brain using quantitative proteomics. Nat Chem Biol. 2007; 3(6):339-48. DOI: 10.1038/nchembio881. View

10.

Bunting K, Rao S, Hardy K, Woltring D, Denyer G, Wang J . Genome-wide analysis of gene expression in T cells to identify targets of the NF-kappa B transcription factor c-Rel. J Immunol. 2007; 178(11):7097-109. DOI: 10.4049/jimmunol.178.11.7097. View

11.

Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A . Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007; 56(11):2759-65. DOI: 10.2337/db07-0156. View

12.

Golks A, Tran T, Goetschy J, Guerini D . Requirement for O-linked N-acetylglucosaminyltransferase in lymphocytes activation. EMBO J. 2007; 26(20):4368-79. PMC: 2034663. DOI: 10.1038/sj.emboj.7601845. View

13.

Xing D, Feng W, Not L, Miller A, Zhang Y, Chen Y . Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol. 2008; 295(1):H335-42. PMC: 2494765. DOI: 10.1152/ajpheart.01259.2007. View

14.

Mauldin J, Nagelin M, Wojcik A, Srinivasan S, Skaflen M, Ayers C . Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation. 2008; 117(21):2785-92. PMC: 2748102. DOI: 10.1161/CIRCULATIONAHA.107.741314. View

15.

Madsen-Bouterse S, Xu Y, Petty H, Romero R . Quantification of O-GlcNAc protein modification in neutrophils by flow cytometry. Cytometry A. 2008; 73(7):667-72. PMC: 3554246. DOI: 10.1002/cyto.a.20569. View

16.

Sayat R, Leber B, Grubac V, Wiltshire L, Persad S . O-GlcNAc-glycosylation of beta-catenin regulates its nuclear localization and transcriptional activity. Exp Cell Res. 2008; 314(15):2774-87. DOI: 10.1016/j.yexcr.2008.05.017. View

17.

Hurtado-Guerrero R, Dorfmueller H, van Aalten D . Molecular mechanisms of O-GlcNAcylation. Curr Opin Struct Biol. 2008; 18(5):551-7. DOI: 10.1016/j.sbi.2008.09.005. View

18.

Yang W, Park S, Nam H, Kim D, Kang J, Kang E . NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci U S A. 2008; 105(45):17345-50. PMC: 2582288. DOI: 10.1073/pnas.0806198105. View

19.

Coornaert B, Carpentier I, Beyaert R . A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2008; 284(13):8217-21. PMC: 2659177. DOI: 10.1074/jbc.R800032200. View

20.

Zou L, Yang S, Champattanachai V, Hu S, Chaudry I, Marchase R . Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. Am J Physiol Heart Circ Physiol. 2008; 296(2):H515-23. PMC: 2643896. DOI: 10.1152/ajpheart.01025.2008. View